Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4Thoracic 3Gastrointestinal 3Sarcoma 1Plasma cell 1Myeloid 1Gynecologic 1Genitourinary 1

Conditions

Stomach Neoplasms 1Sarcoma 1Lung Neoplasms 1Liposarcoma 1Gastrointestinal Stromal Tumors 1Carcinoma, Transitional Cell 1Carcinoma 1Breast Neoplasms 1

Interventions

pembrolizumab 9Gemcitabine 9Cyclophosphamide 8Radiotherapy 7Carboplatin 7Paclitaxel 6Cisplatin 6Trastuzumab 5Irinotecan 5Doxorubicin 5Docetaxel 5Peripheral Blood Stem Cell Transplantation 4Filgrastim 4Capecitabine 4poly ICLC 3pazopanib 3liposomal doxorubicin 3durvalumab 3atezolizumab 3Therapeutics 3Taxes 3Surveys and Questionnaires 3Radiation 3Polymerase Chain Reaction 3Oncolytic Virotherapy 3Letrozole 3Injections 3Fulvestrant 3Fluorodeoxyglucose F18 3Flow Cytometry 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × pemigatinib × Sarcoma × Clear all
NCT06551896 2024-08-13

Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Not yet recruiting
30 enrolled
BreastGastrointestinalGenitourinarySarcomaThoracic

Breast Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Lung Neoplasms, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡